Harrow Health, Inc.
HealthcareNASDAQ:HROW · NASDAQ Global Market
-$0.01 today
Vol 0.74M · Avg 0.75M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-9.8%
avg 14.5%
ROIC
12.7%
avg -27.3%
ROA
-1.3%
avg -22.7%
Analysis
ROIC is currently the strongest return metric at 12.7% versus its period average of -27.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mark L. Baum | CEO, Chairman of the Board & Founder | $1.31M | — | 54 | $3.00M | 8.04% |
Andrew R. Boll | President, Chief Financial Officer & Corporate Secretary | $777,517.00 | — | 44 | $814,679.00 | 2.19% |
Amir W. Shojaei | Chief Scientific Officer | $672,058.00 | — | 58 | $10,000.00 | 0.03% |
Francis W. Mullery | President & Chief Executive Officer of Harrow's ImprimisRx Division | $442,684.00 | — | — | $0.00 | <0.01% |
Frank W. Mullery | President & Chief Executive Officer of Harrow's ImprimisRx Division | $442,684.00 | — | — | $0.00 | <0.01% |
Kim Barratt | Chief Talent Officer | — | — | — | — | — |
Mark A. Mannebach | Head of Regulatory Affairs & Pharmacovigilance | — | — | — | $3.00M | 8.04% |
Brett A. Burrell | Vice President of Legal & Compliance | — | — | — | $8,347.00 | 0.02% |
Michael D. Biega | Vice President of Investor Relations & Communications | — | — | — | — | — |
Patrick W. Sullivan | Chief Commercial Officer | — | — | 50 | $0.00 | <0.01% |
Randall E. Pollard | Chief Accounting Officer | — | — | 54 | $30,000.00 | 0.08% |
Vincent Mair | Senior Vice President of Commercial Operations | — | — | — | — | — |
Prashanth S. Annavajjhala | Chief of Staff | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$468,720.00
Sells
6
$9.18M
Net Sentiment
$8.72M
Net selling
Most Active
Opaleye Management Inc.
6 transactions
Analysis
Insiders reported 4 buys worth $468,720.00 and 6 sells worth $9.18M over the last 12 months. That adds up to net selling of $8.72M. Opaleye Management Inc. was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +359.7% | +37.1% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +359.7% over three years. Forward estimates point to Revenue at +37.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Trevi Therapeutics, Inc.
NASDAQ:TRVI
$2.02B
Dynavax Technologies Corporation
DVAX
$1.82B
Alvotech
NASDAQ:ALVO
$1.30B
BioLife Solutions, Inc.
NASDAQ:BLFS
$1.28B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.22B
Collegium Pharmaceutical, Inc.
NASDAQ:COLL
$1.12B
Evotec SE
NASDAQ:EVO
$966.11M
Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
$885.83M
Tilray Brands, Inc.
NASDAQ:TLRY
$595.63M
Phreesia, Inc.
NYSE:PHR
$560.02M
Who manages HROW?
Harrow Health, Inc. (HROW) lists 13 active executives. The top listed executive is Amir W. Shojaei, Chief Scientific Officer.
Are HROW insiders buying or selling?
Recent insider activity shows net selling of $42.20M.
Explore More
Continue the stock analysis
Jump to another research area for this company.